CIK 0001590750
- Large accelerated filer
Viridian Therapeutics, Inc.DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 471187261
- Phone
- +1 617-272-4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | Harmon Seth Chief Financial Officer | Shares withheld for taxes | −2,031 | $30.19 | $61K | 7,850 |
| 2026-03-03 | Harmon Seth Chief Financial Officer | Exercise or conversion | +6,267 | 9,881 | ||
| 2026-03-03 | Harmon Seth Chief Financial Officer | Shares withheld for taxes | −2,091 | $29.32 | $61K | 7,790 |
| 2026-03-03 | Harmon Seth Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −6,267 | 18,801 | ||
| 2026-03-02 | Harmon Seth Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +102,850 | 102,850 | ||
| 2026-03-02 | Harmon Seth Chief Financial Officer | Grant or award · Restricted Stock Units | +20,550 | 20,550 | ||
| 2025-03-03 | Harmon Seth Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +150,407 | 150,407 | ||
| 2025-03-03 | Harmon Seth Chief Financial Officer | Grant or award · Restricted Stock Units | +25,068 | 25,068 | ||
| 2023-11-10 | Harmon Seth | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 |
Page 1 of 1 · 9 trades